Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients

被引:9
|
作者
Macedo, Luciana Conci [1 ]
Quintero, Fernanda de Cesare [2 ]
Pagliari-E-Silva, Sara [3 ]
Barbosa Pagnano, Katia Borgia [4 ]
Rodrigues, Camila [1 ]
de Alencar, Josiane Bazzo [1 ]
Sell, Ana Maria [2 ]
Laguila Visentainer, Jeane Eliete [2 ]
机构
[1] Univ Estadual Maringa, Biomed & Clin Anal Dept, Post Grad Program Biosci & Physiopathol, BR-87020900 Maringa, Parana, Brazil
[2] Univ Estadual Maringa, Basic Hlth Sci Dept, Ave Colombo 5790, BR-87020900 Maringa, Parana, Brazil
[3] Hosp Canc Maringa, Maringa, Parana, Brazil
[4] Univ Estadual Campinas, Ctr Hematol & Hemoterapia Campinas, Sao Paulo, Brazil
关键词
Myeloproliferative disorders; NECROSIS-FACTOR-ALPHA; PROMOTER POLYMORPHISM; GENETIC POLYMORPHISMS; POLYCYTHEMIA-VERA; SUSCEPTIBILITY; LUNG; REGION;
D O I
10.1016/j.bcmd.2015.12.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The classical chromosome Philadelphia-negative myeloproliferative neoplasms (MPNs) are a group of disorders that share clinical, hematological, and histological features. Proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) are elevated in patients with MPN. The aim of this study was to verify the association between the polymorphisms of TNF gene (-308G/A and-238 G/A) in BCR-ABL-negative MPN in our population. Blood samples obtained from MPN patients were genotyped for the JAK2V617F mutation and both TNF polymorphisms using PCR-RFLP. Thirty three (26.8%) patients with polycythemia vera (PV), 35 (28.7%) essential thrombocythemia (ET), 22 (17.7%) primary myelofibrosis (PMF), and 33 (26.8%) with unclassifiable MPN (MPNu) were included in the study. The JAK2 V617F mutation was detected in 94 (76.42%) patients. Were observed a significant increase on the frequency of the TNF-238 GA genotype in MPN patients compared to controls (OR = 221, 95% Cl = 1.02-4.80, P < 0.04). The distribution of the genotypes and allelic frequencies of TNF-308 was significantly different among the MPNs, JAK2V617F positive, PV and PMF, and controls. Our data has demonstrated that the polymorphisms on TNF-238 GA, TNF-308 GA were associated to MPN development in this population, triggered by JAK2 V617F mutation. (C) 2015 Published by Elsevier Inc.
引用
收藏
页码:54 / 57
页数:4
相关论文
共 50 条
  • [41] REAL TIME DETECTION OF JAK2 V617F IN THE MYELOPROLIFERATIVE DISORDERS
    Goday-Fernandez, A.
    Boyd, E. M.
    Bench, A. J.
    Erber, W. N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 302 - 302
  • [42] JAK2 V617F ALLELE BURDEN IN CHRONIC MYELOPROLIFERATIVE DISEASES
    Skerget, Matevz
    Pajic, Tadej
    Kralj, Eva
    Vuckovic, Josko
    ZDRAVNISKI VESTNIK-SLOVENIAN MEDICAL JOURNAL, 2008, 77 : I57 - I61
  • [43] Rapid detection of JAK2 V617F mutation in myeloproliferative disorders
    Mir, Rashid
    AbuDuhier, Faisal M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders
    Langabeer, S. E.
    Ainle, F. Ni
    Conneally, E.
    Lawler, M.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2007, 176 (02) : 105 - 109
  • [45] Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders
    S. E. Langabeer
    F. Ni Ainle
    E. Conneally
    M. Lawler
    Irish Journal of Medical Science, 2007, 176 : 105 - 109
  • [46] A study of JAK2 (V617F) gene mutation in patients with chronic myeloproliferative disorders
    Hamidah, N. H.
    Farisah, N. R.
    Azlinda, A. B.
    Wong, F. L.
    Das, S.
    Fadillah, S. A. W.
    Ainoon, O.
    CLINICA TERAPEUTICA, 2012, 163 (02): : 109 - 113
  • [47] Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders
    Sazawal, Sudha
    Bajaj, Jyoti
    Chikkara, Sunita
    Jain, Sonal
    Bhargava, Rahul
    Mahapatra, Manoranjan
    Saxena, Renu
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2010, 132 (04) : 423 - 427
  • [48] Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms
    Hinds, David A.
    Barnholt, Kimberly E.
    Mesa, Ruben A.
    Kiefer, Amy K.
    Do, Chuong B.
    Eriksson, Nicholas
    Mountain, Joanna L.
    Francke, Uta
    Tung, Joyce Y.
    Nguyen, Huong
    Zhang, Haiyu
    Gojenola, Linda
    Zehnder, James L.
    Gotlib, Jason
    BLOOD, 2016, 128 (08) : 1121 - 1128
  • [49] BCR::ABL1 translocation and JAK2 V617F mutation testing in myeloproliferative neoplasms
    Paro, M. M. Kardum
    Svabek, Z. Tkalcic
    Horvat, M.
    Martinovic, M.
    Smoljanovic, I. Mandac
    Kolonic, S. Ostojic
    Kristo, D. Radic
    CLINICA CHIMICA ACTA, 2024, 558
  • [50] Myeloproliferative Neoplasms with Concurrent BCR-ABL1 Translocation and JAK2 V617F Mutation
    Soderquist, Craig
    Ewalt, Mark D.
    Czuchlewski, David
    Geyer, Julia
    Rogers, Heesun J.
    Babushok, Daria
    Hexner, Elizabeth
    Orazi, Attilio
    Hsi, Eric D.
    Wang, Sa
    Bueso-Ramos, Carlos E.
    Arber, Daniel A.
    Bagg, Adam
    LABORATORY INVESTIGATION, 2016, 96 : 377A - 377A